Ann: Orthocell commences nerve repair study, page-8

He did. You are quite right. I mistyped in my haste. Apologies.

He now owns 54m shares in MSB or 6.6% as you point out. The company itself owns an additional 60 million; 7.3%.

There is so obviously, and almost laughably, likely to be a partnership announced in CLBP. I argued this with the original SurgCenter investment (I do own MSB - its been an awful investment).

The irony is, SurgCenter is so suitable for an ATI partnership. We've seen how favourable the FDA has been to autologous treatments recently. Its such a shoo-in businesswise. I think ATI would arguably be a far better toe in the water for SC, but hey, they are going in with the big one, a pioneering allogeneic stem cell treatment, with arguably greater execution risks.

I've had ATI, for those I have not bored. Its a 2 x 20 minute in and out job. Quick biopsy. 6-8 week culture of cells. Revisit for quick injection into degenerative tendon. Autologous (no cell rejection risk) tencocyte cells, that can literally only remain tendon cells, not regenerate into other less predictable cells as detractors of MSc cells would argue.